Clinical Trial Update: An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial of sotorasib in KRAS G12C-mutant non-small cell lung cancer with a translational study to identify acquired resistance mechanisms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• sotorasib (sotorasib)

Snippet

Sponsor: Yonsei University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN